Evaluation of the Effects A2B Adenosine Receptor-Agonist (BAY 60–6583) in Induction of Apoptosis in ACHN Renal Cancer Cell Line

Document Type : Original Article (s)

Authors

1 Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: A2B adenosine receptor (A2BAR) is member of the family of seven transmembrane G protein coupled receptor that are activated in high concentration of extracellular adenosine that occur in certain pathophysiological conditions. Activation of the A2B adenosine receptor in tumor cell line limits or promotes tumor growth. In current study, we investigated the role of A2B adenosine receptor-agonist in apoptosis induction in ACHN renal cancer cell line.Methods: ACHN renal cancer cell line was selected to investigate the effect of A2B adenosine receptor-agonist (BAY 60-6583) on apoptosis. The cells were cultured in high glucose Dulbecco's Modified Eagle's Medium (DMEM) (10% FBS and 1% penicillin/streptomycin). Cell viability and apoptosis were evaluated using 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT) assay and Annexin V/propidium iodide (PI), respectively.Findings: Based on MTT assay, treated samples with 50, 100 and 200 μmol of BAY 60-6583 had approximately 50% viability after 48 hours. In addition, based on Annexin V/propidium iodide test, 50 and 100 μmol concentration of BAY 60-658 induced the most apoptosis after 48 hours.Conclusion: According to the results, it can be concluded that BAY 60-6583 induces apoptosis in ACHN cell line with A2B adenosine receptor stimulation, therefore the A2B adenosine receptor-agonists can be used as agent that inhibit cancer growth.

Keywords

References

  1. de Vivar Chevez AR, Finke J, Bukowski R. The role of inflammation in kidney cancer. Adv Exp Med Biol 2014; 38(816): 197-234.
  2. Jin Z, Wallace L, Harper SQ, Yang J. PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development. J Biol Chem 2010; 285(45): 34493-502.
  3. Su Z, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer 2015; 14: 48.
  4. Long JS, Crighton D, O'Prey J, Mackay G, Zheng L, Palmer TM, et al. Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol Cell 2013; 50(3): 394-406.
  5. Wei Q, Costanzi S, Balasubramanian R, Gao ZG, Jacobson KA. A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal 2013; 9(2): 271-80.
  6. Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, et al. Adenosine receptors and cancer. Handb Exp Pharmacol 2009; (193): 399-441.
  7. Aherne CM, Kewley EM, Eltzschig HK. The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta 2011; 1808(5): 1329-39.
  8. Williams M, Jarvis MF. Purinergic and pyrimidinergic receptors as potential drug targets. Biochem Pharmacol 2000; 59(10): 1173-85.
  9. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006; 58(1): 58-86.
  10. Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 2007; 64(12): 1471-83.
  11. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 2003; 100(1): 31-48.
  12. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, et al. Basic research in kidney cancer. Eur Urol 2011; 60(4): 622-33.
  13. Nylander S, Femia EA, Scavone M, Berntsson P, Asztely AK, Nelander K, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013; 11(10): 1867-76.
  14. Hua X, Chason KD, Jania C, Acosta T, Ledent C, Tilley SL. Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation. J Pharmacol Exp Ther 2013; 344(2): 426-35.
  15. Wei CJ, Li W, Chen JF. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim Biophys Acta 2011; 1808(5): 1358-79.
  16. Giorgi I, Nieri P. Adenosine A1 modulators: A patent update (2008 to present). Expert Opin Ther Pat 2013; 23(9): 1109-21.
  17. Kumar V, Sharma A. Adenosine: An endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol 2009; 616(1-3): 7-15.
  18. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53(4): 527-52.
  19. Ahsan MK, Mehal WZ. Activation of adenosine receptor A2A increases HSC proliferation and inhibits death and senescence by down-regulation of p53 and Rb. Front Pharmacol 2014; 5: 69.
  20. Nogi Y, Kanno T, Nakano T, Fujita Y, Tabata C, Fukuoka K, et al. AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis. Cell Physiol Biochem 2012; 30(1): 61-74.
  21. Otsuki T, Kanno T, Fujita Y, Tabata C, Fukuoka K, Nakano T, et al. A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. Cell Physiol Biochem 2012; 30(1): 210-20.
  22. Yaguchi T, Nakano T, Gotoh A, Nishizaki T. Adenosine promotes GATA-2-regulated p53 gene transcription to induce HepG2 cell apoptosis. Cell Physiol Biochem 2011; 28(4): 761-70.
  23. Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Voyno-Yasenetskaya T, et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res 2002; 90(5): 531-8.
  24. Grant MB, Tarnuzzer RW, Caballero S, Ozeck MJ, Davis MI, Spoerri PE, et al. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res 1999; 85(8): 699-706.
  25. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta 2011; 1808(5): 1400-12.
Journal of Isfahan Medical School
Volume 36, Issue 466 - Serial Number 466
January and February 2018
Pages 35-41

Files

History

  • Receive Date: 26 September 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics